{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6a7c4d1991cf66ecf884e337?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs ","description":"<p>On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Susan O’Brien, University of California Irvine, US, delivered a presentation on BTK inhibitors in chronic lymphocytic leukemia: Mechanisms, clinical considerations, and unmet needs.&nbsp;</p><p><br></p><p>This educational resource is independently supported by Eli Lilly and Company. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</p>","author_name":"Scientific Education Support"}